Plain-English translation of NCT07458347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a medication called in people with advanced or metastatic cancers that have a specific genetic mutation called KRAS. The trial will gradually increase the dose in different groups of participants to find the safest and most effective dose. Researchers will carefully monitor how your body responds to the medication and whether it helps slow or shrink your cancer.
Many people with KRAS-mutant cancers—including lung, pancreatic, and colon cancers—run out of effective treatment options. This medication is designed to target the faulty KRAS gene, which may offer hope to patients whose cancers have stopped responding to standard therapies.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth, and your dose may increase over time as the trial progresses and safety is established. You will have regular visits with the research team for blood tests, imaging scans, and physical exams to monitor how the medication is working and whether you are experiencing any side effects. You can continue in the trial as long as the medication is helping you and you can tolerate it.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States